{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-008992","form_type":"8-K","ticker":null,"cik":"0001564824","company_name":"Allakos Inc.","filed_at":"2025-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.016838+00:00","generated_at":"2026-05-27T09:14:03.001623+00:00","sec_items":["2.02","2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Allakos discontinues AK006 after Phase 1 CSU failure, cuts 75% of workforce","bullets":["AK006 Phase 1 CSU study failed: mean UAS7 change -8.2 (AK006) vs -12.4 (placebo); no therapeutic activity.","Workforce reduction of ~75%; ~15 employees to explore strategic alternatives and wind-down trial.","Restructuring costs estimated $34M-$38M, majority paid H1 2025; Dec 31, 2024 cash ~$81M; June 30, 2025 cash est. $35M-$40M.","AK006 was well-tolerated with no serious adverse events, but showed no efficacy versus placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-008992","json":"https://secwatch.observer/filing/0000950170-25-008992.json","markdown":"https://secwatch.observer/filing/0000950170-25-008992.md","text":"https://secwatch.observer/filing/0000950170-25-008992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1564824/000095017025008992/0000950170-25-008992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1564824/000095017025008992/allk-20250127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T09:14:03.001623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7dedf2bd9a5abb85dc4c4afd1f25973e557718b0","claim":"Allakos Inc. announced a restructuring with charges of approximately $34 million to $38 million affecting discontinuation of AK006-related activities across clinical, manufacturing, research and administrative functions (approximately 75%).","evidence_excerpt":"On January 27, 2025, the Company announced plans to discontinue development of AK006. As part of the corporate restructuring, the Company plans to discontinue AK006-related activities across clinical, manufacturing, research and administrative functions. The Company also plans to reduce its workforce by approximately 75%. The total costs related to discontinuing AK006-related activities and reducing the workforce are estimated to be approximately $34 million to $38 million","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1564824/000095017025008992/0000950170-25-008992-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $34 million to $38 million"},{"label":"Affected area","value":"discontinuation of AK006-related activities across clinical, manufacturing, research and administrative functions"},{"label":"Headcount","value":"approximately 75%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}